Potential IPF Treatment AD-214 Works in Inhaled Form, AdAlta Says

Potential IPF Treatment AD-214 Works in Inhaled Form, AdAlta Says

314061

Potential IPF Treatment AD-214 Works in Inhaled Form, AdAlta Says

AdAlta announced that AD-214, its candidate treatment for idiopathic pulmonary fibrosis (IPF), has been successfully made into an aerosol for inhalation — a nebulized form — while retaining the molecular properties that supported its potential effectiveness in preclinical studies. “The results of these studies support AD-214 being delivered by inhalation without losing its ability to bind to CXCR4 and at particle sizes with potential to travel to the furthest reaches of the lungs that are most…

You must be logged in to read/download the full post.